← All stocks

Contineum Therapeutics, Inc.

CTNM Scheduled selling only

CIK 0001855175 #2951 in the set updated 17 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$41.14K

$0.00 on a plan · $41.14K straight out of an exercise

Sold at will

$0.00

0 of 1 sales

Net

−$41.14K

$0.00 against sales at will

By person

3 insiders · 1 transaction

0.4×

Carmine N. Stengone holds only 0.4 times base salary in stock. $283.33K of shares against $655.62K in salary for 2025.

Salary from the company's own proxy. The shares are what Carmine N. Stengone last reported holding, valued at $16.46, the price Class A Common Stock was last bought or sold at on the open market here, on 8 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Stengone Carmine N.

CEO and President

—

$41.14K (1) scheduled

−$41.14K

17,217

0.0745%

$283.33K

0.0%

Lorrain Daniel S.

Chief Scientific Officer

—

135,202

0.5853%

$2.22M

−23.1%

Watkins Tim

CMO & Head of Development

—

8,961

0.0388%

$147.47K

0.0%

Individual transactions

Insider

Date

Role

Action

Price

Amount

Stengone Carmine N.

8 Sep 2026

CEO and President

Sold after exercise

2,500

$16.46

$41.14K

What was left out

Form 4 filings counted 1

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 1

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 2,500

History held since 11 Apr 2024